Oded S. Lieberman
PhD, MBA – CEO
Dr. Lieberman has over 25 years of international experience in corporate leadership, technology development and the successful launch and commercialization of diagnostics, drugs and medical devices.
He has served as CEO of NeuroDerm since December 2007 and was Chairman of the Board between 2005 and 2013. He previously held the positions of CEO and President of Proteologics Ltd., and Vice President of Surgical Products at Omrix Biopharmaceuticals Ltd. (later floated on NASDAQ (OMRX) and acquired by J&J). Prior to Omrix, Dr. Lieberman held senior management positions at Octapharma AG and Boehringer Mannheim GmbH (later Roche Diagnostics) including marketing and business development positions and, in addition, served as chairman and/or a member of the board of several health care companies.
Dr. Lieberman has a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD, Fontainebleau.
MD, MBA – CMO and Product Strategy
Dr. Oren has over 20 years of international pharma experience, including 16 years at Teva Pharmaceuticals, where she served as Medical Director. She was responsible for the clinical development and marketing of innovative drugs in CNS and specifically in Parkinson’s disease.
Dr. Oren has served as VP Clinical and Regulatory Affairs and CMO since September 2008, since the acquisition Dr. Oren assumed the role of CMO and Product Strategy.
Dr. Oren holds an MD from the Sackler School of Medicine, Tel Aviv University and an MBA from the Interdisciplinary Center, Herzliya.
MA – EVP Clinical Development
Ms. Yardeni has over 20 years of experience in the pharmaceutical industry in various capacities, gained within large pharmaceutical companies and CROs. She was previously with Teva Pharmaceutical Industries, most recently as VP, Head of Global Clinical Operation, where she was responsible for the operational execution of global development programs across all indications from Phase I to regulatory approval and commercialization. From 1999 to 2011, Ms. Yardeni held positions of increasing responsibility in the area of Biometrics at Teva, she led strategic planning and execution of outsourcing and off-shoring activities, as well as post-acquisition integration processes for various biometric functions.
Ms. Yardeni joined NeuroDerm in 2016 and served as a COO until the Mitsubishi-Tanabe Pharma Company acquisition, she was then nominated to head the Clinical Development group. She received both her B.A. in Statistics and M.A. in Applied Statistics from Haifa University.
BSc – VP Devices
Mr. Shor has 18 years of experience in the development, registration, production and commercialization of medical devices. Prior to joining in 2016 the company, Mr. Shor was the Chief Executive Officer of PerfAction Technologies, a company that develops technologies and medical devices for drug delivery, where he led the company from the R&D stage to global commercialization. From 2009 to 2013, Mr. Shor was COO of PerfAction Technologies, where he led multi-disciplinary R&D teams that integrated mechanics, electronics, pneumatics and software development. From 2003 to 2009, he held positions of increasing responsibility at GI View, a company focused on developing a new generation of endoscopy products for gastrointestinal applications based on unique visualization and self-propelled pneumatic intubation technology. These positions included Mechanical & System Manager, VP of R&D and COO. Previously Mr. Shor held positions in Mechanical Engineering at Nova and Elan Medical, where he took part in developing a wearable drug delivery pump.
He received his B.Sc. in Mechanical Engineering from Tel Aviv University.
BSc – VP Regulatory Affairs
Ms. Mesika has more than 25 years of R&D and regulatory experience in the pharmaceutical industry working for both medium and large pharmaceutical companies, joined NeuroDerm in 2016. During her six-year tenure at Teva Pharmaceutical Industries, Ms. Mesika was the Global RA leader for biosimilar products in Global R&D and Head of Regulatory Affairs for Specialty Products in Growth Markets region. She was responsible for setting the regulatory strategy for development and registration of innovative drugs, biologics and combination products from various therapeutic areas, including CNS, Pain, Oncology, and Respiratory.
Ms. Mesika holds a BSc in Biology from the Hebrew University in Jerusalem.
PhD – VP Pharmaceutical Development
Adrian joined the NeuroDerm senior leadership team in April 2018 to lead the newly-formed Pharmaceutical Development function. Bringing more than 26 years of experience in the pharmaceutical industry, He was previously VP CMC in Discovery & Product Development in Teva’s Global R&D. Prior to that he held roles of increasing responsibility at Teva, including VP Quality for Global R&D, contributing to the development of important and valuable new therapies such as Copaxone® and Azilect®.
He grew up in London, England, gained a BSc in Chemistry from the University of Manchester and holds an MSc and PhD in Materials from Cranfield University. He conducted post-doctoral research in Applied Chemistry at the Hebrew University of Jerusalem in Israel and is a member of the scientific advisory board of The Dysautonomia Foundation.
BSc, MBA – VP Commercial Operations
Ms. Altman has over 25 years of experience in commercial & business operations in the pharmaceutical and medical devices business environments, leading global brands throughout their life cycle from early development to commercialization.
Since 2000 Ms. Altman held several positions of increasing responsibility leading TEVA’s Global Branded Operations and supply chain group. From the first launch of Teva’s flag ship product Copaxone®, to a multi-billion branded business operations, she was responsible for over 50 marketed & pipeline products in 50 different markets. Since then she served in various capacities working in global, regional and local positions in diversified multi-cultural environments most recently as VP, Commercial Operations International markets and leading Teva’s global ERM function and risk community as Head of Enterprise Risk Management and Business Continuity. Ms. Altman joined NeuroDerm in 2019.
Ms. Altman holds a B.Sc. in Industrial Engineering and Management from the Technion, the Israeli Institute of Technology, an MBA from Tel Aviv University and Global Leadership Program from INSEAD (Fontainebleau).
MSc – VP Human Resources
Ms. Nahmany has over 20 years of experience in organizational transformation, joined NeuroDerm in 2016. Her work is focused on defining organizational strategy, implementing change management, and building leadership teams, with an emphasis on global development. Ms. Nahmany has advised companies in the pharmaceutical, biotech and communications sectors, including leading global companies such as Teva Pharmaceutical Industries. She has also served in various consultancy positions at PricewaterhouseCoopers and McKenzie, and was COO of White Water, focused on smart water network management software.
Ms. Nahmany holds an MSc in Management and Group Dynamics from Tel Aviv University.
MBA, CPA – Head of Finance
Mr. Talbi has 15 years of experience in various finance roles in the biotech industry, in private and public companies, startups and multinational corporates, Joined NeuroDerm in 2018. Prior to joining NeuroDerm, Moshe served as the CFO of FutuRx, a biotech accelerator established by J&J, Takeda and Orbimed which are engaged in early stage novel drug development. Previously Mr. Talbi worked for Gefen Biomed, a publicly traded medical device group of companies (TASE:GEFEN), as Financial Controller and Business Development director. Prior to Gefen, Mr. Talbi served as the financial controller for Novartis Pharma Israel, where he was part of the Israeli site founding team.
Mr. Talbi is a Certified Public Accountant, trained at PWC’s Biotech Assurance group, holds an MBA and a B.A in Accounting & Economics, both from the Recanati Business School, Tel Aviv University.
MSc – VP Planning & Coordination
Mr. Isshiki has served as a Vice President of NeuroDerm since April 2018. He oversees post-merger integration on-site and plays a role for facilitating mutual understanding of two different cultures. Mr. Isshiki has held a variety of research and managerial roles with increasing responsibilities since joining Tanabe Seiyaku in 1994. He previously served as a Senior Manager of Corporate Strategic Planning Department of Mitsubishi Tanabe Pharma Corporation where he was responsible for establishing company’s medium-term business plan and managing R&D projects. Before that Mr. Isshiki had served as a Vice President of Administration of Tanabe Research Laboratories U.S.A. (TRL) from 2011 to 2015. In TRL he was responsible for managing HR, finance, and administrative departments of the restructured research-based subsidiary in the US. Mr. Isshiki received his M.S. in Enzymology from Tohoku University in Japan.